阿拉普利

阿拉普利
臨床資料
AHFS/Drugs.com	國際藥品名稱
給藥途徑	口服
ATC碼	未分配;
法律規範狀態
法律規範	處方藥（℞-only）;
識別資訊
	IUPAC命名法 (2S)-2-[[(2S)-1-[(2S)-3-acetylsulfanyl-2-methylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoic acid; ;
CAS號	74258-86-9
PubChem CID	71992;
ChemSpider	64993 ;
UNII	X39TL7JDPF;
KEGG	D01900 ;
ChEMBL	ChEMBL2103775 ;
CompTox Dashboard（英語：CompTox Chemicals Dashboard） (EPA)	DTXSID3048576 ;
化學資訊
化學式	C20H26N2O5S
摩爾質量	406.50 g·mol−1
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES C[C@H](CSC(=O)C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O;
	InChI InChI=1S/C20H26N2O5S/c1-13(12-28-14(2)23)19(25)22-10-6-9-17(22)18(24)21-16(20(26)27)11-15-7-4-3-5-8-15/h3-5,7-8,13,16-17H,6,9-12H2,1-2H3,(H,21,24)(H,26,27)/t13-,16+,17+/m1/s1 ; Key:FHHHOYXPRDYHEZ-COXVUDFISA-N ;

阿拉普利（INN：alacepril）是一種ACE抑制劑藥物，可用於治療高血壓。該藥物代謝為卡托普利和去乙酰阿拉普利。^[1]阿拉普利主要用於治療高血壓，在某些情況下用於治療腎血管性高血壓。它通常與其他藥物結合使用，特別是其他降血壓藥物，如噻嗪類利尿劑，以最大限度地發揮其功效。^[2]

作用機制

在體內，當阿拉普利經歷脫乙酰化時，它會失去類似於苯丙氨酸的分子，從而將其轉化為卡托普利。^[3]卡托普利通過兩種方式發揮降血壓作用。首先，它抑制血管緊張素1（一種前體分子）轉化為血管緊張素II（一種使血管變窄的血管收縮劑）的過程。其次，卡托普利可以防止緩激肽的分解，緩激肽是一種自然鬆弛血管的血管舒張肽。^[4]

參考資料

^ Alacepril. IBM Micromedex. 24 August 2010 [23 June 2022].
^ Alacepril. DrugCentral online drug compendium. [13 April 2024]. （原始內容存檔於2024-05-01）. It is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. It used for the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics).
^ Campese VM, Lakdawala RS. The Challenges of Blood Pressure Control in Dialysis Patients. Nissenson AR, Fine RN (編). Handbook of dialysis therapy 5th. Philadelphia, PA: Elsevier. 2017. ISBN 978-0-323-39154-2. doi:10.1016/B978-0-323-39154-2.00053-9. The sulfhydryl agents, such as alacepril, delapril, and moveltopril, are prodrugs and thus are converted to captopril in vivo. These sulfhydryl-containing compounds have a slower onset and longer duration of action than captopril.
^ Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clinical and Experimental Immunology. September 2000, 121 (3): 515–522. PMC 1905724  . PMID 10971519. doi:10.1046/j.1365-2249.2000.01323.x.

外部連結

維基共享資源上的相關多媒體資源：阿拉普利

[1] Alacepril. IBM Micromedex. 24 August 2010 [23 June 2022].

[2] Alacepril. DrugCentral online drug compendium. [13 April 2024]. （原始內容存檔於2024-05-01）. It is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. It used for the treatment of essential or renovascular hypertension (usually administered with other drugs, particularly thiazide diuretics).

[3] Campese VM, Lakdawala RS. The Challenges of Blood Pressure Control in Dialysis Patients. Nissenson AR, Fine RN (編). Handbook of dialysis therapy 5th. Philadelphia, PA: Elsevier. 2017. ISBN 978-0-323-39154-2. doi:10.1016/B978-0-323-39154-2.00053-9. The sulfhydryl agents, such as alacepril, delapril, and moveltopril, are prodrugs and thus are converted to captopril in vivo. These sulfhydryl-containing compounds have a slower onset and longer duration of action than captopril.

[4] Odaka C, Mizuochi T. Angiotensin-converting enzyme inhibitor captopril prevents activation-induced apoptosis by interfering with T cell activation signals. Clinical and Experimental Immunology. September 2000, 121 (3): 515–522. PMC 1905724  . PMID 10971519. doi:10.1046/j.1365-2249.2000.01323.x.

[1]

[2]

[3]

[4]